FDA Lifts Clinical Hold on Tabelecleucel Trial for EBV+ Post-Transplant Lymphoproliferative Disease
FDA lifts clinical hold on tabelecleucel IND, enabling trial resumption in EBV+ PTLD following HSCT or SOT in relapsed/refractory patients.
Related Articles
Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer
Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.
Adjuvant Nivolumab Plus Relatlimab Misses the Mark in Resected Stage III to IV Melanoma
Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.
Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer
A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma
Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.
NCCN Adds 2 Tests to CRC Screening Guidelines
The NCCN has added the Shield blood test and the ColoSense test to its colorectal cancer screening guidelines.
OncLive Insider
OncLive Insider puts the power of trusted oncology news and education right at your fingertips. Built for oncology professionals, the app offers quick, convenient access…
Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC
Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.
Consolidation Benmelstobart ± Anlotinib Provides Substantial PFS Benefits in Stage III NSCLC
Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.
OncLive State of the Science Summit | Genitourinary Cancers | Columbia, MD | June 10, 2025
OncLive® State of the Science Summit™ (SOSS) are in-person meetings designed for academic & community-based physicians and health care professionals that provide education on the…
Lifileucel Paves the Way for Evolving Treatment Approaches After PD-1 Inhibition in Advanced Melanoma
Justin Moser, MD, discusses efforts to develop a broader range of immunotherapy approaches for advanced melanoma after PD-1 inhibition.